Once this study is complete, VIRO will be able to complete the cycle to fulfill the manufacturing conditions for production of the validation orders in mid-September of this year. Once manufacturing is complete the clinical trials for module 3 for the EMA permitting will begin in Germany. When Module 3 is complete, the Company will formulate the requirements for modules 4 and 5 for registration in Europe.